Eli Lilly and Company (NYSE:LLY – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Basaglar Global market Report 2025 – Market ... Major players in this growth-driven market include Eli Lilly and Company and Boehringer Ingelheim Pharma GmbH & Co. KG, among others.

These biosimilars are also competing against insulin glargine products that were approved prior to the passing of the biosimilar approval pathway, including Toujeo (Sanofi), Rezvoglar (Eli Lilly), ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...